Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.

Anthony W TolcherRazelle KurzrockVincente ValeroRene GonzalezRebecca S HeistAntoinette R TanJulie Means-PowellTheresa L WernerCarlos BecerraChenxi WangCathrine LeonowensShanker Kalyana-SundaramJoseph F KlehaJennifer GauvinAnthony M D'AmelioCatherine EllisNageatte IbrahimLi Yan

Published in: Cancer chemotherapy and pharmacology (2020)

Continuous and intermittent dosing of trametinib in combination with uprosertib was not tolerated, and minimal clinical activity was observed in all schedules tested.

Keyphrases

pi k akt
signaling pathway
cell proliferation
clinical trial
study protocol
phase iii
open label
high intensity
phase ii
randomized controlled trial
placebo controlled